Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · IEX Real-Time Price · USD
1.01
0.00 (0.00%)
At close: Nov 27, 2023, 4:00 PM
1.06
+0.05 (4.95%)
After-hours: Nov 27, 2023, 7:57 PM EST
Clearside Biomedical Stock Forecast
Stock Price Forecast
According to 4 stock analysts, the average 12-month stock price forecast for CLSD stock stock is $5.25, which predicts an increase of 419.80%. The lowest target is $4.00 and the highest is $6.00. On average, analysts rate CLSD stock stock as a strong buy.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CLSD stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '23 | Jul '23 | Aug '23 | Sep '23 | Oct '23 | Nov '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +494.06% | Nov 14, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +494.06% | Nov 6, 2023 |
| JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +395.05% | Aug 15, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +494.06% | Aug 15, 2023 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +296.04% | Aug 15, 2023 |
Financial Forecast
Revenue This Year
1.38M
from 1.33M
Increased by 4.14%
Revenue Next Year
3.70M
from 1.38M
Increased by 167.80%
EPS This Year
-0.63
from -0.55
EPS Next Year
-0.62
from -0.63
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | 1.8M | 10.1M | 17.5M | 37.5M | 126.5M |
| Avg | 1.4M | 3.7M | 7.7M | 26.8M | 78.3M |
| Low | 980,000 | n/a | n/a | 10.2M | 53.8M |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | 36.2% | 630.2% | 373.5% | 384.3% | 372.1% |
| Avg | 4.1% | 167.8% | 109.4% | 245.7% | 192.3% |
| Low | -26.1% | - | - | 31.5% | 100.8% |
EPS Forecast
| EPS | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | -0.62 | -0.58 | -0.57 | -0.92 | 0.74 |
| Avg | -0.63 | -0.62 | -0.73 | -0.93 | 0.15 |
| Low | -0.65 | -0.64 | -0.81 | -0.92 | -0.39 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.